Q4 2024 Earnings Call Transcript March 18, 2025 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for MiNK Therapeutics in a ...

MiNK Therapeutics (NASDAQ:INKT) just reported results for the first quarter of 2024. MiNK Therapeutics reported earnings per share of -11 cents. This was above the analyst estimate for EPS of -15 ...

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT ...

GRI Bio bolsters IP portfolio with granting of two global patents for Europe & Japan: La Jolla, California Wednesday, April 2, 2025, 14:00 Hrs [IST] GRI Bio, Inc., a biotechnology ...

MiNK Therapeutics Inc (INKT) showcases promising clinical progress and strategic partnerships while navigating financial hurdles and leadership changes.

MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million. Dylan Berman Why Byrna Technologies ...

Interim results demonstrate GRI-0621 to be safe and well-tolerated in the first 12 patients evaluated Interim biomarker data on track for Q2 2025 and topline results expected Q3 2025 Currently ...

“These latest data demonstrate the remarkable potential of combining BOT/BAL with a novel iNKT cell therapy to broaden and intensify immune responses against resistant gastric tumors,” said Dr ...

Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of ...